Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials

ConclusionThe use of the NfL-based prediction model to compensate for clinical heterogeneity in ALS could significantly increase the trial power.NCT00868166, registered March 23, 2009; NCT02306590, registered December 2, 2014.

http://link.springer.com/10.1186/s40035-021-00257-y

Source: Translational Neurodegeneration - August 26, 2021 Category: Neurology Source Type: research

More News: ALS | Brain | Neurology | Statistics | Study